Randomised Assessment of Treatment using Panel Assay of Cardiac markers – a trial of rapid blood testing for acute chest pain in six NHS hospitals around the UK.
To evaluate the clinical effectiveness and cost-effectiveness of the most promising point-of-care cardiac marker panel currently used in the emergency department.
Multi centre randomised controlled trial of point of care markers vs standard care in patients with acute chest pain in the Emergency Department.
Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011;97:190–6.
Fitzgerald P, Goodacre SW, Cross E, Dixon S: Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the randomized assessment of treatment using panel Assay of cardiac markers (RATPAC) trial. Acad Emerg Med 2011; 18(5): 488-95.
Bradburn M, Goodacre SW, Fitzgerald P, Coats T, Gray A, Hassan T, Humphrey J, Kendall J, Smith J, Collinson P; RATPAC Research Team: Interhospital variation in the RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Emerg Med J 2012; 29(3): 233-8.
Goodacre S, Bradburn M, Fitzgerald P Cross E, Collinson P, Gray A and Hall AS. The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technology Assessment. (2011);15(23).
P Collinson, S Goodacre, D Gaze and A Gray. Very Early Diagnosis Of Chest Pain By Point Of Care Testing; Comparison Of The Diagnostic Efficiency Of A Panel Of Cardiac Biomarkers Compared To Troponin Measurement Alone In The Randomised Assessment Of Panel Assay Of Cardiac Markers (RATPAC) Trial. Heart. (2012);98:312-318.
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions